Teladoc Health Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Chuck Divita

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	7.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Chuck Divita (54 yo)

less than a year

Amtszeit

Mr. Charles Divita, III is CEO and Director at Teladoc Health, Inc. since June 2024. He served as Florida Combined Life Insurance Company, Inc. from 2018 to 2024. He had been Executive Vice President of Co...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mala Murthy	Chief Financial Officer	5.4yrs	US$5.94m	0.050% MX$ 16.1m
Michael Waters	Chief Operating Officer	2.3yrs	US$4.80m	0.045% MX$ 14.7m
Adam Vandervoort	Chief Legal Officer & Secretary	9.8yrs	US$3.54m	0.027% MX$ 8.7m
Charles Divita	CEO & Director	less than a year	keine Daten	keine Daten
George Brooks	Co-Founder	22.8yrs	keine Daten	keine Daten
Joseph Catapano	Senior VP & Chief Accounting Officer	less than a year	keine Daten	keine Daten
Nikolaos Nanis	Chief Technology Officer	no data	keine Daten	0.044% MX$ 14.2m
Patrick Feeley	Vice President of Investor Relations	no data	keine Daten	keine Daten
Andrew Turitz	Executive Vice President of Corporate Development	9.8yrs	US$2.07m	0.012% MX$ 3.9m
Stephany Verstraete	Chief Marketing Officer & Engagement Officer	8.8yrs	US$2.01m	0.028% MX$ 9.2m
Arnnon Geshuri	Chief People Officer	4.1yrs	keine Daten	0.026% MX$ 8.4m
Daniel Trencher	Chief Strategy Officer	9.8yrs	keine Daten	0.018% MX$ 5.9m

7.1yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: TDOC *Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.1 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charles Divita	CEO & Director	less than a year	keine Daten	keine Daten
Thomas McKinley	Independent Director	15yrs	US$290.00k	0.023% MX$ 7.3m
David Shedlarz	Independent Director	8.2yrs	US$294.49k	0.0086% MX$ 2.8m
David Snow	Independent Non-Executive Chairman	10.8yrs	US$332.50k	0.069% MX$ 22.3m
Sandra Fenwick	Independent Director	4yrs	US$280.00k	0.023% MX$ 7.6m
Kenneth Paulus	Independent Director	7.8yrs	US$285.00k	0% MX$ 0
Mark Smith	Independent Director	6.1yrs	US$283.00k	0.0049% MX$ 1.6m
Catherine Jacobson	Independent Director	4.8yrs	US$280.00k	0.012% MX$ 3.8m
J. Evans	Independent Director	1.2yrs	US$264.69k	0.0024% MX$ 763.0k

6.1yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: TDOC *Die Vorstandsmitglieder gelten als erfahren (6.1 Jahre durchschnittliche Amtszeit).

Teladoc Health Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Independent Director recently bought Mex$605k worth of stock

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Independent Director recently bought Mex$528k worth of stock

Independent Director recently bought Mex$1.6m worth of stock

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Insider recently sold Mex$220k worth of stock

Recent updates

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Third quarter 2024 earnings released: US$0.19 loss per share (vs US$0.35 loss in 3Q 2023)

Teladoc Health, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Independent Director recently bought Mex$605k worth of stock

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Independent Director recently bought Mex$528k worth of stock

Independent Director recently bought Mex$1.6m worth of stock

Second quarter 2024 earnings released: US$4.92 loss per share (vs US$0.40 loss in 2Q 2023)

Teladoc Health, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Dynamic Index

Teladoc Health, Inc. Releases New Data from Two Studies

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Insider recently sold Mex$220k worth of stock

Insider recently sold Mex$220k worth of stock

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit against Teladoc Health, Inc

Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2023)

Teladoc Health, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Teladoc Health, Inc. Announces Chief Executive Officer Changes

New major risk - Share price stability

Full year 2023 earnings released: US$1.34 loss per share (vs US$84.60 loss in FY 2022)

Teladoc Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Teladoc Health, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Now 21% undervalued

Forecast to breakeven in 2026

Insufficient new directors

Teladoc Health, Inc. Announces Resignation of Claus T. Jensen, PhD as Chief Innovation Officer Effective December 1, 2023

New minor risk - Shareholder dilution

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.45 loss in 3Q 2022)

Teladoc Health, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Teladoc Health, Inc. Appoints Eric Evans to Board of Directors

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$19.22 loss in 2Q 2022)

Teladoc Health, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Year Ending December 31, 2023

Teladoc Health, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Teladoc Health, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Growth Index

Chief People Officer recently sold Mex$440k worth of stock

First quarter 2023 earnings released: US$0.42 loss per share (vs US$41.58 loss in 1Q 2022)

Chief People Officer recently sold Mex$535k worth of stock

Full year 2022 earnings released: US$84.60 loss per share (vs US$2.73 loss in FY 2021)

Now 20% undervalued after recent price drop

Teladoc Health, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Now 27% undervalued after recent price drop

Teladoc Health Launches Fully Integrated Whole-Person Care Experience with New App

Now 24% undervalued after recent price drop

Chief People Officer recently sold Mex$1.3m worth of stock

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.45 loss per share (vs US$0.53 loss in 3Q 2021)

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Teladoc Health Inc. Appoints Laizer Kornwasser as President, Enterprise Growth & Global Markets

Teladoc Health, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Now 20% undervalued after recent price drop

Teladoc Health, Inc.(NYSE:TDOC) dropped from FTSE All-World Index (USD)

Now 24% undervalued after recent price drop

Chief People Officer recently sold Mex$2.8m worth of stock

Second quarter 2022 earnings released: US$19.22 loss per share (vs US$0.86 loss in 2Q 2021)

Now 24% undervalued

Teladoc Health, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022

Teladoc Health, Inc. Appoints Mike Waters as Chief Operating Officer

Teladoc Health’S Integrated Chronic Care Solutions Deliver Improved Health Outcomes

Teladoc Health, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Jakubowitz Law Reminds Teladoc Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Gainey McKenna & Egleston Files Class Action Lawsuit Against Teladoc Health, Inc

Chief People Officer recently sold Mex$1.8m worth of stock

Teladoc Health, Inc. Reports Goodwill Impairment for the First Quarter Ended March 31, 2022